Trastuzumab deruxtecan shows promising results in HER2-positive breast cancer with brain metastases
A study demonstrated the effectiveness of trastuzumab deruxtecán in patients with advanced or metastatic breast cancer HER2 positive, even with brain metastases.[1] Lead author Dr. Nancy Lin, from the Dana-Farber Cancer Institute in Boston, United States, presented these primary results from the DESTINY-Breast12 trial at the Annual Meeting of the European Society for Medical Oncology … Read more